Ablation of Breast Cancer Stem Cells with Radiation

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Translational oncology (Impact Factor: 2.88). 08/2011; 4(4):227-33. DOI: 10.1593/tlo.10247
Source: PubMed


Tumor radioresistance leads to recurrence after radiation therapy. The radioresistant phenotype has been hypothesized to reside in the cancer stem cell (CSC) component of breast and other tumors and is considered to be an inherent property of CSC. In this study, we assessed the radiation resistance of breast CSCs using early passaged, patient-derived xenografts from two separate patients. We found a patient-derived tumor in which the CSC population was rapidly depleted 2 weeks after treatment with radiation, based on CD44(+) CD24(-) lin(-) phenotype and aldehyde dehydrogenase 1 immunofluorescence, suggesting sensitivity to radiotherapy. The reduction in CSCs according to phenotypic markers was accompanied by a decrease in functional CSC activity measured by tumor sphere frequency and the ability to form tumors in mice. In contrast, another patient tumor sample displayed enrichment of CSC after irradiation, signifying radioresistance, in agreement with others. CSC response to radiation did not correlate with the level of reactive oxygen species in CSC versus non-CSC. These findings demonstrate that not all breast tumor CSCs are radioresistant and suggest a mechanism for the observed variability in breast cancer local recurrence.

Download full-text


Available from: Steven Zielske, Mar 21, 2014
  • Source
    • "CSCs from one patients were rapidly depleted 2 weeks after treatment with radiation, resulting in a significant decrease in tumor sphere frequency and tumorigenic capacity. In contrast, CSCs from the other patient showed enrichment after radiation and resistance to therapy, suggesting that CSC variance may exist in individual patients [56] . Therefore, therapeutics that target different CSC subtypes is likely required. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, it has become increasingly apparent that noncoding RNAs (ncRNA) are of crucial importance for human cancer. The functional relevance of ncRNAs is particularly evident for microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). miRNAs are endogenously expressed small RNA sequences that act as post-transcriptional regulators of gene expression and have been extensively studied for their roles in cancers, whereas lncRNAs are emerging as important players in the cancer paradigm in recent years. These noncoding genes are often aberrantly expressed in a variety of human cancers. However, the biological functions of most ncRNAs remain largely unknown. Recently, evidence has begun to accumulate describing how ncRNAs are dysregulated in cancer and cancer stem cells, a subset of cancer cells harboring self-renewal and differentiation capacities. These studies provide insight into the functional roles that ncRNAs play in tumor initiation, progression, and resistance to therapies, and they suggest ncRNAs as attractive therapeutic targets and potentially useful diagnostic tools.
    Ai zheng = Aizheng = Chinese journal of cancer 11/2013; 32(11):582-593. DOI:10.5732/cjc.013.10170 · 2.16 Impact Factor
  • Source
    • "Consistent with this finding, knockdown of CD44 expression has been found to induce breast CSCs to differentiate into regular tumor cells without the capacity to self-renew (defined as non-CSCs) [13]. Nevertheless, in certain breast cancer patients, CD44+/CD24- cells are still sensitive to radiotherapy, suggesting that not all breast CSCs are radioresistant [14] and that not all CD44+/CD24- cells are CSCs. Indeed, clinical data have indicated that there is no significant correlation between CD44+/CD24-/low tumor cell prevalence and tumor progression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Identification of cancer stem cells (CSCs) and their behaviors will provide insightful information for the future control of human cancers. This study investigated CD44 and CD24 cell surface markers as breast cancer CSC markers in vitro and in vivo. Flow cytometry with CD44 and CD24 markers was used to sort breast cancer MCF7 cells for scanning electron microscopy (SEM), tumor cell invasion assay, and nude mouse xenograft assay. Flow cytometry assay using CD44 and CD24 markers sorted MCF7 cells into four subsets, i.e., CD44+/CD24-/low, CD44-/CD24+, CD44+/CD24+, and CD44-/CD24-. The SEM data showed that there were many protrusions on the surface of CD44+/CD24-/low cells. CD44+/CD24-/low cells had many microvilli and pseudopodia. The CD44+/CD24-/low cells had a higher migration and invasion abilities than that of the other three subsets of the cells. The in vivo tumor formation assay revealed that CD44+/CD24- cells had the highest tumorigenic capacity compared to the other three subsets. CD44 and CD24 could be useful markers for identification of breast CSCs because CD44+/CD24-/low cells had unique surface ultrastructures and the highest tumorigenicity and invasive abilities.
    Cancer Cell International 06/2013; 13(1):62. DOI:10.1186/1475-2867-13-62 · 2.77 Impact Factor
  • Source
    • "Furthermore, pancreatic cancer stem cells are sensitive to gemcitabine because we found that secondary tumor initiation is delayed in response to gemcitabine. Thus, although many studies have found that cancer stem cells are relatively resistant to therapy, the current study and our previous findings regarding the sensitivity of some breast cancer stem cells to radiation [42] suggest that it is premature to conclude that cancer stem cell resistance is universal. Although the combination of gemcitabine and AZD7762 reduced both the percentage of marker-positive cells and their tumor-initiating capacity, after tumor initiation, tumor growth rates were similar across treatment groups (Figure 3A). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Checkpoint kinase 1 (Chk1) inhibition sensitizes pancreatic cancer cells and tumors to gemcitabine. We hypothesized that Chk1 inhibition would sensitize pancreatic cancer stem cells to gemcitabine. We tested this hypothesis by using two patient-derived xenograft models (designated J and F) and the pancreatic cancer stem cell markers CD24, CD44, and ESA. We determined the percentage of marker-positive cells and their tumor-initiating capacity (by limiting dilution assays) after treatment with gemcitabine and the Chk1 inhibitor, AZD7762. We found that marker-positive cells were significantly reduced by the combination of gemcitabine and AZD7762. In addition, secondary tumor initiation was significantly delayed in response to primary tumor treatment with gemcitabine + AZD7762 compared with control, gemcitabine, or AZD7762 alone. Furthermore, for the same number of stem cells implanted from gemcitabine- versus gemcitabine + AZD7762-treated primary tumors, secondary tumor initiation at 10 weeks was 83% versus 43%, respectively. We also found that pS345 Chk1, which is a measure of DNA damage, was induced in marker-positive cells but not in the marker-negative cells. These data demonstrate that Chk1 inhibition in combination with gemcitabine reduces both the percentage and the tumor-initiating capacity of pancreatic cancer stem cells. Furthermore, the finding that the Chk1-mediated DNA damage response was greater in stem cells than in non-stem cells suggests that Chk1 inhibition may selectively sensitize pancreatic cancer stem cells to gemcitabine, thus making Chk1 a potential therapeutic target for improving pancreatic cancer therapy.
    Neoplasia (New York, N.Y.) 06/2012; 14(6):519-25. DOI:10.1158/1538-7445.AM2011-3919 · 4.25 Impact Factor
Show more